Search Result
Results for "
brain metabolism
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
39
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-118635
-
-
-
- HY-113524
-
|
Endogenous Metabolite
|
Neurological Disease
|
N-Acetyl-L-aspartic acid is a derivative of Aspartic acid (HY-N0666) and endogenous compound. N-Acetyl-L-aspartic acid acts as an acetyl donor. N-Acetyl-L-aspartic acid is involved in brain metabolism. N-Acetyl-L-aspartic acid is used in the research of neurodegenerative diseases (such as Canavan disease) .
|
-
-
- HY-N0229
-
-
-
- HY-W010388AS
-
-
-
- HY-W096638A
-
(S)-Glycerolphosphocholine
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Glycerophosphocholine ((S)-Glycerolphosphocholine) is an intracellular metabolite during phosphatidylcholine metabolism and can be used to study the endogenous choline supply of cells. Glycerophosphocholine is used as a supplement in research into brain disorders .
|
-
-
- HY-101102
-
|
Dopamine Receptor
|
Neurological Disease
|
7-Hydroxy-DPAT hydrobromide is a selective D3 dopamine receptor agonist, exhibiting significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain.
|
-
-
- HY-14197
-
M&B 9302
|
Monoamine Oxidase
|
Neurological Disease
|
Clorgyline (M&B 9302) is an orally active, blood-brain barrier permeable and selective monoamine oxidase A (MAO-A) inhibitor. Clorgyline's selective inhibition of MAO-A leads to reduced metabolism of neurotransmitters such as serotonin (5-hydroxytryptamine), which accumulates in the brain. Clorgyline can be used in the study of depression and neurodegenerative diseases .
|
-
-
- HY-B0762
-
O-Acetyl-L-carnitine hydrochloride; ALCAR hydrochloride
|
Caspase
Apoptosis
|
Neurological Disease
|
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-113218
-
O-Acetyl-L-carnitine; ALCAR
|
Caspase
Apoptosis
|
Neurological Disease
|
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-106110
-
|
Prostaglandin Receptor
|
Metabolic Disease
|
OP-2507 is a prostacyclin analog. OP-2507 can increase brain glucose levels in mice, suppress the breakdown of energy metabolism under hypoxic conditions, and has a protective effect against changes in cyclic nucleotides in hypoxic brain tissue (specifically, an increase in cyclic AMP and a decrease in cyclic GMP). OP-2507 provides protective effects against brain hypoxia and edema .
|
-
-
- HY-N0229S13
-
-
-
- HY-N0229S3
-
L-2-Aminopropionic acid-d4
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine-d4 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S12
-
L-2-Aminopropionic acid-d3
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine-d3 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-E70467
-
|
Cytochrome P450
|
Metabolic Disease
|
Human CYP2D6, Low-Reductase a recombinant CYP2D6, is a member of the CYP enzyme family. CYP2D6 plays important roles in the liver and in the brain with regards to xenobiotic metabolism .
|
-
-
- HY-E70461
-
|
Cytochrome P450
|
Metabolic Disease
|
Human CYP2D6, High-Reductase, a recombinant CYP2D6, is a member of the CYP enzyme family. CYP2D6 plays important roles in the liver and in the brain with regards to xenobiotic metabolism .
|
-
-
- HY-W250118
-
|
Liposome
Autophagy
|
Neurological Disease
Metabolic Disease
|
Cephalin form bovine brain is an orally active phospholipid widely present in organisms.Cephalin form bovine brain participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Cephalin form bovine brain enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity .
|
-
-
- HY-N0229S8
-
L-2-Aminopropionic acid-13C3
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine- 13C3 is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S9
-
L-2-Aminopropionic acid-13C2
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine- 13C2 is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S2
-
L-2-Aminopropionic acid-15N
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine- 15N is the 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system .
|
-
-
- HY-19648B
-
HOE-427 TFA
|
nAChR
|
Neurological Disease
|
Ebiratide (HOE-427) TFA is an ACTH 4-9 derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy. Ebiratide TFA enhances acetycholine (ACh) metabolism in rat brain .
|
-
-
- HY-19648
-
HOE-427 free base
|
Melanocortin Receptor
nAChR
|
Neurological Disease
|
Ebiratide (HOE-427 free base) is an ACTH 4-9 derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy. Ebiratide enhances acetycholine (ACh) metabolism in rat brain .
|
-
-
- HY-P6306
-
|
Apolipoprotein
Amyloid-β
|
Neurological Disease
Metabolic Disease
|
CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
|
-
-
- HY-N0229S7
-
-
-
- HY-N0229S6
-
-
-
- HY-N0229S4
-
L-2-Aminopropionic acid-13C,d1
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine- 13C,d is the 13C- and deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S1
-
L-2-Aminopropionic acid-1-13C
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine-1- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S16
-
|
Endogenous Metabolite
|
Metabolic Disease
|
L-Alanine-d3-1 is the deuterium labeled L-Alanine . L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system .
|
-
-
- HY-P6306A
-
|
Apolipoprotein
Amyloid-β
|
Neurological Disease
Metabolic Disease
|
CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
|
-
-
- HY-148165
-
-
-
- HY-N0229S15
-
L-2-Aminopropionic acid-13C2,15N
|
Endogenous Metabolite
|
Metabolic Disease
|
L-Alanine- 13C2, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S10
-
-
-
- HY-N0229S14
-
-
-
- HY-N0229S11
-
-
-
- HY-B0762S
-
O-Acetyl-L-carnitine-d3 hydrochloride
|
Isotope-Labeled Compounds
Caspase
Apoptosis
|
Neurological Disease
|
Acetyl-L-carnitine-d3 (O-Acetyl-L-carnitine-d3) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-B0762S1
-
O-Acetyl-L-carnitine-d3-1 hydrochloride
|
Isotope-Labeled Compounds
Caspase
Apoptosis
|
Neurological Disease
|
Acetyl-L-carnitine-d3-1 (O-Acetyl-L-carnitine-d3-1) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-W765177
-
O-Acetyl-L-carnitine hydrochloride-13C3; ALCAR hydrochloride-13C3
|
Isotope-Labeled Compounds
Apoptosis
Caspase
|
Neurological Disease
|
Acetyl-L-carnitine hydrochloride- 13C3 (O-Acetyl-L-carnitine hydrochloride- 13C3) is the 13C-labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-N0229S19
-
-
-
- HY-N0229S
-
-
-
- HY-N0229S5
-
L-2-Aminopropionic acid-13C3,15N,d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine- 13C3, 15N,d4 is the deuterium, 13C-, and 15-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-P2048
-
|
Apoptosis
GLUT
AMPK
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .
|
-
-
- HY-P2048A
-
|
AMPK
GLUT
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
MOTS-c (human) acetate is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .
|
-
-
- HY-B1334A
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
|
-
-
- HY-B1334
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .
|
-
-
- HY-18078
-
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC50 andED50 of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .
|
-
-
- HY-B1804
-
Trioctanoin; Glyceryl trioctanoate
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-16731
-
EVT 302; RG1577; RO4602522
|
Monoamine Oxidase
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity .
|
-
-
- HY-W012426
-
MDBP
|
Biochemical Assay Reagents
|
Neurological Disease
|
1-Piperonylpiperazine (MDBP) is metabolized by demethylenation and subsequent methylation to N-(4-hydroxy-3-methoxybenzyl)piperazine followedby partial glucuronidation or sulfation. 1-Piperonylpiperazine can alter the disposition and metabolism of 3,4-methylenedioxymethamphetamine (MDMA) in the brain and in peripheral organs. 1-Piperonylpiperazine can inhibit the MDMA-induced neurotoxicity .
|
-
-
- HY-129982
-
|
Apical Sodium-Dependent Bile Acid Transporter
|
Metabolic Disease
|
SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
|
-
-
- HY-N4190
-
1,6-O,O-Diacetylbritannilactone; Di-O-acetylbritannilactone
|
NO Synthase
|
Neurological Disease
Inflammation/Immunology
|
Britannilactone diacetate (1,6-O,O-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect. Britannilactone diacetate exhibits activity against NO production induced by LPS in BV-2 microglial cells with the EC50 value of 6.3 μM. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption, distribution, metabolism, excretion, and toxicity (ADMET) property .
|
-
-
- HY-148114
-
|
Autophagy
|
Cancer
|
MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP (HY-119624). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggers methuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells .
|
-
- HY-B1334AR
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline (maleate) (Standard) is the analytical standard of Perhexiline (maleate). This product is intended for research and analytical applications. Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
|
-
- HY-D0186
-
|
Endogenous Metabolite
Thymidylate Synthase
|
Infection
|
2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
|
-
- HY-113524S
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
|
N-Acetyl-L-aspartic acid-d3 is the deuterium labeled N-Acetyl-L-aspartic acid (HY-113524). N-Acetyl-L-aspartic acid is a derivative of Aspartic acid (HY-N0666) and endogenous compound. N-Acetyl-L-aspartic acid acts as an acetyl donor. N-Acetyl-L-aspartic acid is involved in brain metabolism. N-Acetyl-L-aspartic acid is used in the research of neurodegenerative diseases (such as Canavan disease) .
|
-
- HY-12688
-
|
Endogenous Metabolite
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
Succinyl phosphonate is an α-ketoglutarate dehydrogenase (KGDHC) inhibitor, effective inhibits (KGDHC) in muscle, bacterial, brain, and cultured human fibroblasts . Succinyl phosphonate trisodium salt is an 2-oxoglutarate dehydrogenase (OGDH) inhibitor, impairs viability of cancer cells in a cell-specific metabolism-dependent manner . Succinyl phosphonate trisodium salt inhibits the glutamate-induced ROS production in glutamate-stimulated hippocampal neurons in situ .
|
-
- HY-12688A
-
|
Endogenous Metabolite
Reactive Oxygen Species (ROS)
|
Neurological Disease
Metabolic Disease
Cancer
|
Succinyl phosphonate trisodium salt is an α-ketoglutarate dehydrogenase (KGDHC) inhibitor, effective inhibits (KGDHC) in muscle, bacterial, brain, and cultured human fibroblasts . Succinyl phosphonate trisodium salt is an 2-oxoglutarate dehydrogenase (OGDH) inhibitor, impairs viability of cancer cells in a cell-specific metabolism-dependent manner . Succinyl phosphonate trisodium salt inhibits the glutamate-induced ROS production in glutamate-stimulated hippocampal neurons in situ .
|
-
- HY-B1804S1
-
Trioctanoin-d50; Glyceryl trioctanoate-d50
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin-d50 (Trioctanoin-d50) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-B1804S2
-
Trioctanoin-d15; Glyceryl trioctanoate-d15
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin-d15 (Trioctanoin-d15) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-113524R
-
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
N-Acetyl-L-aspartic acid (Standard) is the analytical standard of N-Acetyl-L-aspartic acid (HY-113524). This product is intended for research and analytical applications. N-Acetyl-L-aspartic acid is a derivative of Aspartic acid (HY-N0666) and endogenous compound. N-Acetyl-L-aspartic acid acts as an acetyl donor. N-Acetyl-L-aspartic acid is involved in brain metabolism. N-Acetyl-L-aspartic acid is used in the research of neurodegenerative diseases (such as Canavan disease) .
|
-
- HY-B1804S
-
Trioctanoin-13C3; Glyceryl trioctanoate-13C3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin- 13C3 (Trioctanoin- 13C3) is a 13C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-N0385
-
|
NO Synthase
AMPK
CaMK
NF-κB
Keap1-Nrf2
|
Cardiovascular Disease
Inflammation/Immunology
|
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .
|
-
- HY-N0303
-
|
Mitochondrial Metabolism
Apoptosis
|
Neurological Disease
|
Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
|
-
- HY-W587827
-
Thiamine triphosphate
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Thiamine triphosphoric acid ester (TTP), a neuroactive compound, is a triphosphate derivative of the vitamin thiamine. Thiamine triphosphoric acid ester exists in microorganisms, animal organs and plants. Thiamine triphosphoric acid ester is transiently produced in response to amino acid starvation in E. coli, while constitutively producing at a low rate in mammalian cells. Thiamine triphosphoric acid ester can be synthesized by two different enzymes (AK1 in the cytosol and FoF1-ATP synthase in brain mitochondria). Thiamine triphosphoric acid ester has a basic role in cell metabolism or cell signaling .
|
-
- HY-B0311D
-
(S)-(-)-Carbidopa hydrochloride
|
Aryl Hydrocarbon Receptor
|
Cancer
|
Carbidopa hydrochloride ((S)-(-)-Carbidopa hydrochloride) is a drug used to inhibit Parkinson's disease, which has the activity of inhibiting the peripheral metabolism of levodopa. Carbidopa hydrochloride can increase the proportion of peripheral levodopa penetrating the blood-brain barrier, thereby enhancing its effect on the central nervous system. Carbidopa hydrochloride has also been found to be an aryl hydrocarbon receptor (AhR) ligand with anticancer activity, which can inhibit the growth of pancreatic cancer cells and tumors. The selective AhR regulation properties of carbidopa hydrochloride provide potential prospects for its clinical application .
|
-
- HY-W778990
-
|
Isotope-Labeled Compounds
Thymidylate Synthase
Endogenous Metabolite
|
Infection
|
2-Deoxyuridine-1,2,3,4,5- 13C5 is the 13C-labeled 2'-Deoxyuridine (HY-D0186). 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
|
-
- HY-118816
-
11-epi PGF2α-EA; 11β-PGF2α-EA; 11β-Prostamide F2α
|
Drug Metabolite
|
Metabolic Disease
|
11β-Prostaglandin F2α ethanolamide (11β-PGF2α-EA) is the theoretical hepatic metabolite of PGD2-EA, produced during COX-2 metabolism of the endogenous cannabinoid AEA which is found in brain, liver, and other mammalian tissues.1 AEA can be used directly by COX-2 and specific PG synthase to produce ethanolamide congeners of the classical PGs. PGD2-EA is formed in activated RAW 264.7 cells treated with AEA.
|
-
- HY-152943
-
-
- HY-P3801
-
DiMe-C7
|
Neurokinin Receptor
|
Others
Neurological Disease
Metabolic Disease
|
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .
|
-
- HY-162373
-
|
Amylases
Glycosidase
P-glycoprotein
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
|
-
- HY-13409A
-
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
|
-
- HY-N5027
-
Oxyberberin; Berlambine; 8-Oxoberberine
|
Others
|
Infection
Neurological Disease
Inflammation/Immunology
|
Oxyberberine (Oxyberberin; Berlambine) is an orally effective heme oxygenase HO-1 agonist that can activate antioxidant mechanisms by regulating the PI3K/Akt/AMPK signaling pathway. Oxyberberine induces HO-1 expression, increases SOD and GSH-Px activity, inhibits NF-κB-mediated inflammatory responses, and improves insulin sensitivity and glucose metabolism. Oxyberberine has anti-diabetic, neuroprotective, anti-inflammatory and antioxidant effects, and can be used to study type 2 diabetes, traumatic brain injury (TBI) and inflammatory bowel disease .
|
-
- HY-13409
-
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
|
-
- HY-N0303R
-
|
Reference Standards
Mitochondrial Metabolism
Apoptosis
|
Neurological Disease
|
Idebenone (Standard) is the analytical standard of Idebenone. This product is intended for research and analytical applications. Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
|
-
- HY-D0186R
-
|
Reference Standards
Endogenous Metabolite
Thymidylate Synthase
|
Infection
|
2'-Deoxyuridine (Standard) is the analytical standard of 2'-Deoxyuridine. This product is intended for research and analytical applications. 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
In Vitro:The interaction between the 2-deoxyuridine and the column increases the duration of retention of 2-deoxyuridine .
Gradient elution with sodium acetate buffer-ACN eluent on two ZIC-HILIC homemade columns separates 2-deoxyuridine in under 9 min .
In Vivo:2'-Deoxyuridine (34.42 ng/mL, gavage, 15 min) passes the blood-brain barrier (BBB) to enter the hippocampus of mice brain .
2'-Deoxyuridine (20 mg/kg, gavage, daily for 4 weeks) improves cognition and memory loss and attenuates the damage to the hippocampus in Aβ25-35-induced mice model .
|
-
- HY-13409B
-
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
SB 242084 monohydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
|
-
- HY-173513
-
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Neurological Disease
|
IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression .
|
-
- HY-W777283
-
|
Isotope-Labeled Compounds
Apoptosis
Mitochondrial Metabolism
|
Neurological Disease
|
Idebenone- 13C,d3 is the deuterium labeled and 13C-labeled Idebenone (HY-N0303). Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
|
-
- HY-W017540
-
|
ATP Synthase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
- HY-13409AR
-
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
SB 242084 (dihydrochloride) (Standard) is the analytical standard of SB 242084 (dihydrochloride). This product is intended for research and analytical applications. SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
|
-
- HY-13409R
-
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
SB 242084 (Standard) is the analytical standard of SB 242084. This product is intended for research and analytical applications. SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
|
-
- HY-N0059
-
|
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N0059S5
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose-d5 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-W017540S
-
|
Isotope-Labeled Compounds
ATP Synthase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
- HY-114118
-
Semaglutide
Maximum Cited Publications
18 Publications Verification
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-N7082
-
|
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinopyranose is a rare aldehyde pentose, and its ring-opened form is D-arabinose (HY-N0059). D-arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-W016409
-
Protocatechuic acid ethyl ester
|
HIF/HIF Prolyl-Hydroxylase
Reactive Oxygen Species (ROS)
NO Synthase
Autophagy
Apoptosis
|
Metabolic Disease
Cancer
|
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
|
-
- HY-114118B
-
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide acetate is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-N0059S4
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose-d2 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N0059S
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose- 13C is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N0059S6
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose-d6 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N0059R
-
|
Reference Standards
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose (Standard) is the analytical standard of D-Arabinose. This product is intended for research and analytical applications. D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N0059S2
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose- 13C-2 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N0059S1
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose- 13C-1 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-114118A
-
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-N0059S3
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinose- 13C-3 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-N7082S
-
|
Isotope-Labeled Compounds
Parasite
Bacterial
AMPK
PPAR
|
Infection
Neurological Disease
Metabolic Disease
|
D-Arabinopyranos- 13C5 is 13C labeled D-Arabinopyranos (HY-N7082). D-Arabinopyranose is a rare aldehyde pentose, and its ring-opened form is D-arabinose (HY-N0059). D-arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
- HY-114118F
-
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-114118S3
-
|
Isotope-Labeled Compounds
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Metabolic Disease
|
Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-W778057
-
Protocatechuic acid ethyl ester-13C3
|
Reactive Oxygen Species (ROS)
|
Cancer
|
Ethyl 3,4-Dihydroxybenzoate- 13C3 (Protocatechuic acid ethyl ester- 13C3) is the 13C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
|
-
- HY-W016409R
-
Protocatechuic acid ethyl ester (Standard)
|
Reference Standards
HIF/HIF Prolyl-Hydroxylase
Reactive Oxygen Species (ROS)
NO Synthase
Autophagy
Apoptosis
|
Metabolic Disease
Cancer
|
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
|
-
- HY-N0229R
-
Alanine (Standard)
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
L-Alanine (Standard) is the analytical standard of L-Alanine. This product is intended for research and analytical applications. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
In Vitro: The viability of both hiPSCs, 201B7 cells and ehiPSCs decrease with an increase in L-Alanine concentration, and reach 7.5±1.3% and 3.7±0.7% respectively at 1.2 M of L-Alanine. On the other hand, no decrease in the viability of hFBs and hSkMCs are observed. Although the viability of iCMs slightly decreases along with the increase of the L-Alanine concentration, viability of iCMs at 1.2 M concentration of L-Alanine, 49.4±6.9%, is significantly higher than that of undifferentiated iPSCs, 201B7 cells and ehiPSCs (p< 0.01). The viability of hiPSCs, 201B7 cells and ehiPSCs, drastically decrease even after 2 or 4 h treatment. In contrast, the viability of hFBs fails to decrease at 1, 2, and 4 h and shows a small decrease at 24 h treatment. The viability of 201B7 cells in suspension culture decreases to 11.8±6.0% following treatment with 1.2 M L-Alanine for 2 h, whereas that of hFBs is 72.9±14.2% .
|
-
-
-
HY-L155
-
|
512 compounds
|
Mitochondria, as the main place of energy supply in life, is essential to maintain normal life activities. Mitochondrial dysfunction is associated with common diseases, such as cardiovascular diseases, neurodegenerative diseases, diabetes and cancer. The heart, brain and liver rely heavily on mitochondrial function as the main organs for drug metabolism. In addition, mitochondria is also a target of many drugs, some of which induce organotoxicity by inducing mitochondrial toxicity.
MCE contains 512 mitochondrial toxic compounds, which can be used as tool compounds for drug development and disease mechanism research.
|
Cat. No. |
Product Name |
Type |
-
- HY-114118F
-
|
Fluorescent Dyes/Probes
|
Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
Cat. No. |
Product Name |
Type |
-
- HY-W250118
-
|
Drug Delivery
|
Cephalin form bovine brain is an orally active phospholipid widely present in organisms.Cephalin form bovine brain participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Cephalin form bovine brain enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-19648B
-
HOE-427 TFA
|
nAChR
|
Neurological Disease
|
Ebiratide (HOE-427) TFA is an ACTH 4-9 derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy. Ebiratide TFA enhances acetycholine (ACh) metabolism in rat brain .
|
-
- HY-P6306
-
|
Apolipoprotein
Amyloid-β
|
Neurological Disease
Metabolic Disease
|
CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
|
-
- HY-P6306A
-
|
Apolipoprotein
Amyloid-β
|
Neurological Disease
Metabolic Disease
|
CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
|
-
- HY-P2048
-
|
Apoptosis
GLUT
AMPK
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .
|
-
- HY-P2048A
-
|
AMPK
GLUT
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
MOTS-c (human) acetate is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .
|
-
- HY-P3801
-
DiMe-C7
|
Neurokinin Receptor
|
Others
Neurological Disease
Metabolic Disease
|
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .
|
-
- HY-114118
-
Semaglutide
Maximum Cited Publications
18 Publications Verification
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-114118B
-
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide acetate is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-114118A
-
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-19648
-
HOE-427 free base
|
Melanocortin Receptor
nAChR
|
Neurological Disease
|
Ebiratide (HOE-427 free base) is an ACTH 4-9 derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy. Ebiratide enhances acetycholine (ACh) metabolism in rat brain .
|
-
- HY-114118F
-
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-113524
-
-
-
- HY-N0229
-
-
-
- HY-W096638A
-
-
-
- HY-B0762
-
O-Acetyl-L-carnitine hydrochloride; ALCAR hydrochloride
|
Alkaloids
Structural Classification
Other Alkaloids
Source classification
Endogenous metabolite
|
Caspase
Apoptosis
|
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-113218
-
O-Acetyl-L-carnitine; ALCAR
|
Structural Classification
Natural Products
Animals
Source classification
|
Caspase
Apoptosis
|
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-B1804
-
-
-
- HY-D0186
-
-
-
- HY-12688A
-
-
-
- HY-113524R
-
-
-
- HY-12688
-
-
-
- HY-N0385
-
|
Cardiovascular Disease
Structural Classification
Monophenols
Classification of Application Fields
Source classification
Lignans
Phenols
Phenylpropanoids
Plants
Schisandraceae
Schisandra chinensis (Turcz.) Baill.
Disease Research Fields
|
NO Synthase
AMPK
CaMK
NF-κB
Keap1-Nrf2
|
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .
|
-
-
- HY-N5027
-
-
-
- HY-D0186R
-
|
Structural Classification
Natural Products
Immune System Disorder
Microorganisms
Source classification
Disease markers
Endogenous metabolite
|
Reference Standards
Endogenous Metabolite
Thymidylate Synthase
|
2'-Deoxyuridine (Standard) is the analytical standard of 2'-Deoxyuridine. This product is intended for research and analytical applications. 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
In Vitro:The interaction between the 2-deoxyuridine and the column increases the duration of retention of 2-deoxyuridine .
Gradient elution with sodium acetate buffer-ACN eluent on two ZIC-HILIC homemade columns separates 2-deoxyuridine in under 9 min .
In Vivo:2'-Deoxyuridine (34.42 ng/mL, gavage, 15 min) passes the blood-brain barrier (BBB) to enter the hippocampus of mice brain .
2'-Deoxyuridine (20 mg/kg, gavage, daily for 4 weeks) improves cognition and memory loss and attenuates the damage to the hippocampus in Aβ25-35-induced mice model .
|
-
-
- HY-N0059
-
-
-
- HY-N7082
-
-
-
- HY-W016409
-
Protocatechuic acid ethyl ester
|
Structural Classification
Arachis hypogaea L.
Classification of Application Fields
Leguminosae
Source classification
Phenols
Polyphenols
Metabolic Disease
Plants
Disease Research Fields
|
HIF/HIF Prolyl-Hydroxylase
Reactive Oxygen Species (ROS)
NO Synthase
Autophagy
Apoptosis
|
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
|
-
-
- HY-N0059R
-
|
Structural Classification
Human Gut Microbiota Metabolites
Microorganisms
Source classification
Endogenous metabolite
Saccharides
|
Reference Standards
Parasite
Bacterial
AMPK
PPAR
|
D-Arabinose (Standard) is the analytical standard of D-Arabinose. This product is intended for research and analytical applications. D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-W016409R
-
Protocatechuic acid ethyl ester (Standard)
|
Structural Classification
Arachis hypogaea L.
Leguminosae
Source classification
Phenols
Polyphenols
Plants
|
Reference Standards
HIF/HIF Prolyl-Hydroxylase
Reactive Oxygen Species (ROS)
NO Synthase
Autophagy
Apoptosis
|
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
|
-
-
- HY-N0229R
-
Alanine (Standard)
|
Structural Classification
Human Gut Microbiota Metabolites
Microorganisms
Source classification
Disease markers
Amino acids
Endogenous metabolite
Cancer
|
Reference Standards
Endogenous Metabolite
|
L-Alanine (Standard) is the analytical standard of L-Alanine. This product is intended for research and analytical applications. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
In Vitro: The viability of both hiPSCs, 201B7 cells and ehiPSCs decrease with an increase in L-Alanine concentration, and reach 7.5±1.3% and 3.7±0.7% respectively at 1.2 M of L-Alanine. On the other hand, no decrease in the viability of hFBs and hSkMCs are observed. Although the viability of iCMs slightly decreases along with the increase of the L-Alanine concentration, viability of iCMs at 1.2 M concentration of L-Alanine, 49.4±6.9%, is significantly higher than that of undifferentiated iPSCs, 201B7 cells and ehiPSCs (p< 0.01). The viability of hiPSCs, 201B7 cells and ehiPSCs, drastically decrease even after 2 or 4 h treatment. In contrast, the viability of hFBs fails to decrease at 1, 2, and 4 h and shows a small decrease at 24 h treatment. The viability of 201B7 cells in suspension culture decreases to 11.8±6.0% following treatment with 1.2 M L-Alanine for 2 h, whereas that of hFBs is 72.9±14.2% .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W010388AS
-
|
Creatine-d3 (hydrate) is a deuterium labeled Creatine hydrate. Creatine hydrate is pivotal in energy metabolism of muscle and brain cells, both in physiological and in pathological conditions .
|
-
-
- HY-N0229S13
-
|
L-Alanine-d7 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S3
-
|
L-Alanine-d4 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S12
-
1 Publications Verification
|
L-Alanine-d3 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S8
-
|
L-Alanine- 13C3 is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S9
-
|
L-Alanine- 13C2 is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S2
-
|
L-Alanine- 15N is the 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system .
|
-
-
- HY-N0229S6
-
|
L-Alanine-3- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S4
-
|
L-Alanine- 13C,d is the 13C- and deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S7
-
|
L-Alanine-2- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S1
-
|
L-Alanine-1- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S16
-
|
L-Alanine-d3-1 is the deuterium labeled L-Alanine . L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system .
|
-
-
- HY-N0229S15
-
|
L-Alanine- 13C2, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S10
-
|
L-Alanine- 13C3, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S14
-
|
L-Alanine- 15N,d4 is the deuterium and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S11
-
|
L-Alanine-1- 13C, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-B0762S
-
|
Acetyl-L-carnitine-d3 (O-Acetyl-L-carnitine-d3) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-B0762S1
-
|
Acetyl-L-carnitine-d3-1 (O-Acetyl-L-carnitine-d3-1) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-W765177
-
|
Acetyl-L-carnitine hydrochloride- 13C3 (O-Acetyl-L-carnitine hydrochloride- 13C3) is the 13C-labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
|
-
-
- HY-N0229S19
-
|
L-Alanine-1,2- 13C2 (Alanine- 13C2) is 13C labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S
-
|
L-Alanine-2- 13C, 15Nis the 13C-labeled and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-N0229S5
-
|
L-Alanine- 13C3, 15N,d4 is the deuterium, 13C-, and 15-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
|
-
-
- HY-113524S
-
|
N-Acetyl-L-aspartic acid-d3 is the deuterium labeled N-Acetyl-L-aspartic acid (HY-113524). N-Acetyl-L-aspartic acid is a derivative of Aspartic acid (HY-N0666) and endogenous compound. N-Acetyl-L-aspartic acid acts as an acetyl donor. N-Acetyl-L-aspartic acid is involved in brain metabolism. N-Acetyl-L-aspartic acid is used in the research of neurodegenerative diseases (such as Canavan disease) .
|
-
-
- HY-B1804S1
-
|
Tricaprilin-d50 (Trioctanoin-d50) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-B1804S2
-
|
Tricaprilin-d15 (Trioctanoin-d15) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-B1804S
-
|
Tricaprilin- 13C3 (Trioctanoin- 13C3) is a 13C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-W778990
-
|
2-Deoxyuridine-1,2,3,4,5- 13C5 is the 13C-labeled 2'-Deoxyuridine (HY-D0186). 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
|
-
-
- HY-W777283
-
|
Idebenone- 13C,d3 is the deuterium labeled and 13C-labeled Idebenone (HY-N0303). Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
|
-
-
- HY-N0059S5
-
|
D-Arabinose-d5 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-W017540S
-
|
Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
-
- HY-N0059S4
-
|
D-Arabinose-d2 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-N0059S
-
|
D-Arabinose- 13C is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-N0059S6
-
|
D-Arabinose-d6 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-N0059S2
-
|
D-Arabinose- 13C-2 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-N0059S1
-
|
D-Arabinose- 13C-1 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-N0059S3
-
|
D-Arabinose- 13C-3 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-N7082S
-
|
D-Arabinopyranos- 13C5 is 13C labeled D-Arabinopyranos (HY-N7082). D-Arabinopyranose is a rare aldehyde pentose, and its ring-opened form is D-arabinose (HY-N0059). D-arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082) .
|
-
-
- HY-114118S3
-
|
Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-W778057
-
|
Ethyl 3,4-Dihydroxybenzoate- 13C3 (Protocatechuic acid ethyl ester- 13C3) is the 13C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-W250118
-
|
|
Phospholipids
|
Cephalin form bovine brain is an orally active phospholipid widely present in organisms.Cephalin form bovine brain participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Cephalin form bovine brain enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity .
|
-
- HY-148165
-
|
|
Nucleosides and their Analogs
C
|
L-Cytidine is an L-configurational form of Cytidine (HY-B0158). L-Cytidine is a pyrimidine nucleoside, a component of RNA. Cytidine can control the glial glutamate cycle, affect brain phospholipid metabolism, catecholamine synthesis and mitochondrial function .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: